EUVIMEDObjevte EUVIMED
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open access · CC BY 4.0

A Randomized, Double‐Blinded, Placebo‐Controlled QTc Study to Evaluate BIA 28–6156 Effect on Cardiac Repolarization in Healthy Volunteers

Isa Peixoto, Dana Hilt, Teresa Carvalho, João Reis, Helena Gama, Joerg Holenz

Clinical Pharmacology in Drug Development · 2026-04 · 15 (4)

DOI: 10.1002/cpdd.70055 ↗

At a glance

Randomisierte kontrollierte Studie in Clinical Pharmacology in Drug Development, published online on 2026-04-09. Written by Isa Peixoto and 5 co-authors. Institution: Research & Development, BIAL-Portela & Ca, S.A, Porto, Portugal. Major MEDLINE topics: Heart Rate. 34 references. The full text is freely available (open access, CC BY 4.0). Funded by: BIAL R&D Investments.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Mutations in the GBA1 gene, encoding beta‐glucocerebrosidase (GCase), are the most common genetic risk factor for Parkinson's Disease (PD). BIA 28–6156, an allosteric activator of GCase, is under development for the treatment of GBA‐associated PD. This Phase 1, randomized, double‐blind, placebo‐controlled, crossover study assessed the impact of BIA 28–6156 on QT interval corrected (QTc) for heart rate (HR) based on the Fridericia correction (QTcF) in 37 healthy subjects. Participants received single doses of 60 or 150 mg BIA 28–6156, 400 mg moxifloxacin, or placebo in a cross‐over design. The relationship between BIA 28–6156 plasma levels and QTcF changes (ΔQTcF) was analyzed to exclude a ΔΔQTcF > 10 ms. Heart rate, PR, and QRS intervals, electrocardiogram (ECG) waveform morphology, and adverse events (AEs) were also evaluated. The concentration‐QTc analysis indicated no effect on ΔΔQTcF exceeding 10 ms up to BIA 28–6156 plasma levels of ≈7150 ng/mL. No clinically significant effects on ECG parameters were observed, and BIA 28–6156 was generally well tolerated, with no deaths or serious AEs. This study concluded that BIA 28–6156 has no clinically relevant impact on ECG parameters, confirming a negative thorough QT/QTc study.

Subjects

MeSH terms (MEDLINE)

Heart RateHumansDouble-Blind MethodMaleAdultElectrocardiographyFemaleCross-Over StudiesYoung AdultHealthy VolunteersDose-Response Relationship, DrugMiddle AgedGlucosylceramidaseMoxifloxacin

Author keywords

BIA 28–6156GBA activatorQTQTccardiac repolarization

Substances

GlucosylceramidaseMoxifloxacin

Authors and institutions

  • Research & Development, BIAL-Portela & Ca, S.A, Porto, Portugal.
  • Actinogen Medical, Sydney, Australia.

Funding

  • BIAL R&D Investments

Cite

APA

Peixoto, I., Hilt, D., Carvalho, T., Reis, J., Gama, H., & Holenz, J. (2026). A Randomized, Double‐Blinded, Placebo‐Controlled QTc Study to Evaluate BIA 28–6156 Effect on Cardiac Repolarization in Healthy Volunteers. Clinical Pharmacology in Drug Development, 15(4). https://doi.org/10.1002/cpdd.70055

Vancouver

Peixoto I, Hilt D, Carvalho T, Reis J, Gama H, Holenz J. A Randomized, Double‐Blinded, Placebo‐Controlled QTc Study to Evaluate BIA 28–6156 Effect on Cardiac Repolarization in Healthy Volunteers. Clinical Pharmacology in Drug Development. 2026;15(4). doi:10.1002/cpdd.70055

BibTeX
@article{Peixoto2026,
  author = {Peixoto, Isa and Hilt, Dana and Carvalho, Teresa and Reis, João and Gama, Helena and Holenz, Joerg},
  title = {A Randomized, Double‐Blinded, Placebo‐Controlled QTc Study to Evaluate BIA 28–6156 Effect on Cardiac Repolarization in Healthy Volunteers},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  volume = {15},
  number = {4},
  doi = {10.1002/cpdd.70055}
}
Start for free →